Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers. Results of a randomized FOLFA phase II trial
ANNÉE
2022
AUTEURS
Legoux JL, Faroux R, Barrière N, Le Malicot K, Tougeron D, Lorgis V, Guerin-Meyer V, Bourgeois V, Malka D, Aparicio T, Baconnier M, Lebrun-Ly V, Egreteau M, Khemissa F, Akouz, Lepage C, Boige V
CONGRÈS/REVUE
ASCO
LIEN PUBLICATIONS ASSOCIÉES